Phase II study on the efficacy and safety of Lapatinib administered beyond disease progression and combined with vinorelbine in HER-2/neu– positive advanced breast cancer: results of the CECOG LaVie trial

BACKGROUND: Vinorelbine constitutes effective chemotherapy for metastatic breast cancer (MBC) and acts synergistically with trastuzumab in HER-2/neu positive disease. The present study was set out to evaluate the efficacy and safety of vinorelbine when combined with lapatinib, an anti-HER2 tyrosine-...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:BMC Cancer
Prif Awduron: Thallinger, Christiane, Lang, Istvan, Kuhar, Cvetka Grasic, Bartsch, Rupert, Singer, Christian F., Petruzelka, Lubos, Melichar, Bohuslav, Knittelfelder, Regina, Brodowicz, Thomas, Zielinski, Christoph
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2016
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4758093/
https://ncbi.nlm.nih.gov/pubmed/26887956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2171-y
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg